**Author details**

Micaelo Ânia 1 , Rodriguez Emilio 2 , Millan Angel <sup>3</sup> , Gongora Rafael 1,4 and Fuentes Manuel 1,4\* [11] Lazarovits J, Chen YY, Sykes EA, Chan WCW. Nanoparticle – Blood interactions: The implications on solid tumour targeting. Chemical Communications. 2015;**51**:2756-2767

Protein Interactions and Nanomaterials: A Key Role of the Protein Corona in Nanobiocompatibility

http://dx.doi.org/10.5772/intechopen.75501

41

[12] Dobrovolskaia MA et al. Interaction of colloidal gold nanoparticles with human blood: Effects on particle size and analysis of plasma protein binding profiles. Nanomedicine.

[13] Walkey CD, Olsen JB, Guo H, Emili A, Chan WCW. Nanoparticle size and surface chemistry determine serum protein adsorption and macrophage uptake. Journal of the

[14] Anderson NL et al. The human plasma proteome. Molecular & Cellular Proteomics.

[15] Ke PC, Lin S, Parak WJ, Davis TP, Caruso F. A decade of the protein corona. ACS Nano.

[16] Wang B et al. Modulating protein amyloid aggregation with nanomaterials. Environmental

[17] Casals E, Pfaller T, Duschl A, Oostingh GJ, Puntes V. Time evolution of the nanoparticle

[18] Jung S-Y et al. The Vroman effect: A molecular level description of fibrinogen displace-

[19] Cedervall T et al. Understanding the nanoparticle – Protein corona using methods to quantify exchange rates and affinities of proteins for nanoparticles. Proceedings of the

[20] Dobrovolskaia MA et al. Protein corona composition does not accurately predict hematocompatibility of colloidal gold nanoparticles. Nanomedicine. 2014;**10**:1453-1463 [21] Dell'Orco D, Lundqvist M, Oslakovic C, Cedervall T, Linse S. Modeling the time evolution of the nanoparticle-protein corona in a body fluid. PLoS One. 2010;**5**:1-8

[22] Lundqvist M et al. The evolution of the protein corona around nanoparticles : A test

[23] Lundqvist M et al. Nanoparticle size and surface properties determine the protein corona with possible implications for biological impacts. Proceedings of the National

[24] Owens DE, Peppas NA. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. International Journal of Pharmaceutics. 2006;**307**:93-102

[25] Dobrovolskaia MA, Aggarwal P, Hall JB, McNeil SE. Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanopar-

[26] Monopoli MP et al. Physical-chemical aspects of protein corona: Relevance to in vitro and in vivo biological impacts of nanoparticles. Journal of the American Chemical

ticle biodistribution. Molecular Pharmaceutics. 2008;**5**:487-495

ment. Journal of the American Chemical Society. 2003;**125**:12782-12786

2009;**5**:106-117

2004;**3**:311-326

2017;**11**:11773-11776

Science: Nano. 2017;**4**:1772-1783

study. ACS Nano. 2011;**5**:7503-7509

Society. 2011;**133**:2525-2534

Academy of Sciences. 2008;**105**:14265-14270

American Chemical Society. 2012;**134**:2139-2147

protein corona. ACS Nano. 2010;**4**:3623-3632

National Academy of Sciences. 2007;**104**:2050-2055

\*Address all correspondence to: mfuentes@usal.es

1 Cancer Research Center (IBMCC/CSIC/USAL/IBSAL), Department of Medicine, General Cytometry Service-Nucleus, University of Salamanca-CSIC, IBSAL, Salamanca, Spain

2 Department of Inorganic Chemistry, Faculty of Pharmacy, University of Salamanca, Salamanca, Spain

3 Department of Condensed Matter Physics and Materials, Research Institute of Aragon, University of Zaragoza, Zaragoza, Spain

4 Proteomics Unit, Cancer Research Center, IBSAL, University of Salamanca, CSIC, Salamanca, Spain
